Chris Holland

3.7k total citations · 1 hit paper
25 papers, 929 citations indexed

About

Chris Holland is a scholar working on Ophthalmology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Chris Holland has authored 25 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Ophthalmology, 10 papers in Oncology and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Chris Holland's work include Ocular Oncology and Treatments (10 papers), Acute Lymphoblastic Leukemia research (8 papers) and CAR-T cell therapy research (6 papers). Chris Holland is often cited by papers focused on Ocular Oncology and Treatments (10 papers), Acute Lymphoblastic Leukemia research (8 papers) and CAR-T cell therapy research (6 papers). Chris Holland collaborates with scholars based in United States, Germany and United Kingdom. Chris Holland's co-authors include Geoff Lockett, Ian Blackman, Max S. Topp, Gerhard Zugmaier, Nicola Gökbuget, Ralf C. Bargou, Svenja Neumann, Albrecht Reichle, Matthias Stelljes and Hermann Einsele and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Chris Holland

23 papers receiving 881 citations

Hit Papers

Phase II Trial of the Ant... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
    2014 488 citations Max S. Topp, Nicola Gökbuget et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris Holland United States 9 603 351 210 188 176 25 929
Hun Ju Lee United States 22 1.2k 1.9× 134 0.4× 309 1.5× 942 5.0× 226 1.3× 114 2.0k
Barbara Withers Australia 16 242 0.4× 34 0.1× 199 0.9× 74 0.4× 115 0.7× 36 849
Michael Dickinson Australia 26 1.4k 2.4× 87 0.2× 343 1.6× 1.1k 6.1× 348 2.0× 188 2.8k
Mark Stewart United States 14 352 0.6× 72 0.2× 73 0.3× 96 0.5× 43 0.2× 54 1.2k
William Stevenson Australia 20 221 0.4× 97 0.3× 204 1.0× 112 0.6× 525 3.0× 74 1.5k
S. Krishnaswami United States 11 265 0.4× 38 0.1× 397 1.9× 63 0.3× 169 1.0× 31 1.2k
Michael G. Martin United States 16 294 0.5× 40 0.1× 47 0.2× 115 0.6× 52 0.3× 69 865
Kazuyoshi� Ishii Japan 16 155 0.3× 25 0.1× 203 1.0× 104 0.6× 277 1.6× 103 874
Elisa Thomas Norway 16 191 0.3× 48 0.1× 174 0.8× 39 0.2× 391 2.2× 24 1.1k
Luz Muñoz Spain 15 191 0.3× 82 0.2× 141 0.7× 63 0.3× 308 1.8× 37 799

Countries citing papers authored by Chris Holland

Since Specialization
Citations

This map shows the geographic impact of Chris Holland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Holland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Holland more than expected).

Fields of papers citing papers by Chris Holland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Holland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Holland. The network helps show where Chris Holland may publish in the future.

Co-authorship network of co-authors of Chris Holland

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Holland. A scholar is included among the top collaborators of Chris Holland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Holland. Chris Holland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sullivan, Ryan J., Laura Collins, Manuel Rodrigues, et al.. (2023). Abstract 1035: Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma. Cancer Research. 83(7_Supplement). 1035–1035. 1 indexed citations
2.
Hamid, Omid, Jessica C. Hassel, Alexander N. Shoushtari, et al.. (2023). Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. Journal for ImmunoTherapy of Cancer. 11(6). e006747–e006747. 22 indexed citations
3.
Feng, Dan, Laura Collins, Margaret K. Callahan, et al.. (2023). Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.. Journal of Clinical Oncology. 41(16_suppl). 9589–9589. 4 indexed citations
4.
Piulats, Josep M., Alexander N. Shoushtari, Sebastian Ochsenreither, et al.. (2022). Overall survival (OS) in metastatic uveal melanoma: A summary of recent prospective trials.. Journal of Clinical Oncology. 40(16_suppl). e21598–e21598. 1 indexed citations
5.
Butler, Marcus O., Takami Sato, Richard D. Carvajal, et al.. (2021). Abstract CT038: Kinetics of radiographic response for tebentafusp (tebe) in previously treated metastatic uveal melanoma (mUM) patients (pts) achieving prolonged survival. Cancer Research. 81(13_Supplement). CT038–CT038. 3 indexed citations
6.
Hassel, Jessica C., Piotr Rutkowski, Jean‐François Baurain, et al.. (2021). Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.. Journal of Clinical Oncology. 39(15_suppl). 9527–9527. 8 indexed citations
7.
Piperno‐Neumann, Sophie, Jessica C. Hassel, Piotr Rutkowski, et al.. (2021). Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma. Cancer Research. 81(13_Supplement). CT002–CT002. 13 indexed citations
8.
Wang, Zheng, Alicia Zhang, Yuqi Chen, Qui Tran, & Chris Holland. (2020). Type I error inflation of log-rank test with small sample size : A permutation approach and simulation studies. 53(2). 93–109. 1 indexed citations
9.
Orloff, Marlana, Joseph J. Sacco, Paul Nathan, et al.. (2020). Abstract 3295: Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma. Cancer Research. 80(16_Supplement). 3295–3295. 4 indexed citations
10.
Zugmaier, Gerhard, Chris Holland, Youssef Hijazi, et al.. (2017). Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Experimental Hematology and Oncology. 6(1). 14–14. 53 indexed citations
11.
Zugmaier, Gerhard, Nicola Gökbuget, Matthias Klinger, et al.. (2015). Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 126(24). 2578–2584. 115 indexed citations
12.
Zhu, Min, Jessica Johnson, Chris Holland, et al.. (2015). Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. Journal of Clinical Oncology. 33(15_suppl). 2561–2561. 6 indexed citations
13.
Topp, Max S., Matthias Stelljes, Gerhard Zugmaier, et al.. (2015). Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL).. Journal of Clinical Oncology. 33(15_suppl). 7051–7051. 6 indexed citations
14.
15.
Holland, Chris. (2010). The Google Settlement: a Brief Overview. Legal Information Management. 10(3). 181–183.
16.
Liere, Diederik W. van, Peter Vervest, Benn R. Konsynski, & Chris Holland. (2010). Theme of the Special Issue – IS in interorganizational networks. European Journal of Information Systems. 19(4). 432–435. 3 indexed citations
17.
Naudé, Pete, et al.. (2000). The Benefits of IT-Based Supply Chains-Strategic or Operational?. Journal of Business-to-Business Marketing. 7(1). 45–67. 26 indexed citations
18.
Holland, Chris, et al.. (1997). Archaeology online: New life for old dead things. First Monday.
19.
Holland, Chris & Geoff Lockett. (1992). IT strategy in retailing: organizational change and future direction. The Journal of Strategic Information Systems. 1(3). 134–142. 4 indexed citations
20.
Holland, Chris, Geoff Lockett, & Ian Blackman. (1992). Planning for electronic data interchange. Strategic Management Journal. 13(7). 539–550. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hun Ju Lee Breakdown of academic impact, for papers by Barbara Withers Breakdown of academic impact, for papers by Michael Dickinson Breakdown of academic impact, for papers by Mark Stewart Breakdown of academic impact, for papers by William Stevenson Breakdown of academic impact, for papers by S. Krishnaswami Breakdown of academic impact, for papers by Michael G. Martin Breakdown of academic impact, for papers by Kazuyoshi� Ishii Breakdown of academic impact, for papers by Elisa Thomas Breakdown of academic impact, for papers by Luz Muñoz
Rankless by CCL
2026